Hi Sore, a recent study in 2020 found that the mean annualized cost of Ruxolitnib for the treatment of Chronic GVHD was $$223,564, I havent seen you crying over this.
MSB's sr-aGVHD treatment licensed in Japan has a treatment cost of ~$115,000-$175,000. It will probably be priced closer to ~$200,000 in the US similar to Prochymal in Canada.
https://ashpublications.org/blood/article/136/Supplement%201/14/473080/Costs-and-Adverse-Events-Associated-with-Ibrutinib
https://www.google.com/amp/s/bioinformant.com/price-of-cell-therapy-products/amp/
Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT, page-155
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |